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EMERGING INVESTIGATORS
Risk Factors for Heart Failure
20-Year Population-Based Trends by Sex, Socioeconomic Status, and Ethnicity
Claire A. Lawson, PhD; Francesco Zaccardi, PhD; Iain Squire, MD; Hajra Okhai, MSc; Melanie Davies, PhD;  
Weiting Huang, PhD; Mamas Mamas, PhD; Carolyn S.P. Lam, PhD; Kamlesh Khunti, PhD; Umesh T. Kadam, PhD
BACKGROUND: There are multiple risk factors for heart failure, but contemporary temporal trends according to sex, socioeconomic 
status, and ethnicity are unknown.
METHODS: Using a national UK general practice database linked to hospitalizations (1998–2017), 108 638 incident heart 
failure patients were identified. Differences in risk factors among patient groups adjusted for sociodemographic factors and 
age-adjusted temporal trends were investigated using logistic and linear regression.
RESULTS: Over time, a 5.3 year (95% CI, 5.2–5.5) age difference between men and women remained. Women had higher 
blood pressure, body mass index, and cholesterol than men (P<0.0001). Ischemic heart disease prevalence increased for 
all to 2006 before reducing in women by 0.5% per annum, reaching 42.7% (95% CI, 41.7–43.6), but not in men, remaining 
at 57.7% (95% CI, 56.9–58.6; interaction P=0.002). Diabetes mellitus prevalence increased more in men than in women 
(interaction P<0.0001). Age between the most deprived (74.6 years [95% CI, 74.1–75.1]) and most affluent (79.9 [95% CI, 
79.6–80.2]) diverged (interaction P<0.0001), generating a 5-year gap. The most deprived had significantly higher annual 
increases in comorbidity numbers (+0.14 versus +0.11), body mass index (+0.14 versus +0.11 kg/m2), and lower smoking 
reductions (−1.2% versus −1.7%) than the most affluent. Ethnicity trend differences were insignificant, but South Asians 
were overall 6 years and the black group 9 years younger than whites. South Asians had more ischemic heart disease 
(+16.5% [95% CI, 14.3–18.6]), hypertension (+12.5% [95% CI, 10.5–14.3]), and diabetes mellitus (+24.3% [95% CI, 
22.0–26.6]), and the black group had more hypertension (+12.3% [95% CI, 9.7–14.8]) and diabetes mellitus (+13.1% [95% 
CI, 10.1–16.0]) but lower ischemic heart disease (−10.6% [95% CI, −13.6 to −7.6]) than the white group.
CONCLUSIONS: Population groups show distinct risk factor trend differences, indicating the need for contemporary tailored 
prevention programs.
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Heart failure (HF) is reaching epidemic propor-tions in aging populations globally,1 with increas-ing burden and costs projected over the next 2 
decades.2 HF is a complex clinical syndrome with sex,3 
socioeconomic,4 and ethnic5,6 disparities. HF results 
from several different etiological pathways, each influ-
enced by wide-ranging individual, clinical, and environ-
mental risk factors. Reasons for group disparities in 
the burden and outcomes of HF are multifactorial but 
likely include variations in genetic, environmental, and 
physiological susceptibility to different pathophysiologi-
cal mechanisms, increased exposure to risk factors, and 
decreased access to health care.
To stem epidemic growth, public health approaches 
need to be responsive to social and population dynam-
ics and to target the highest risk groups with tailored 
prevention strategies that include the most relevant and 
potentially modifiable risk factors. Yet, contemporary pop-
ulation-based trend data on known risk factors among 
different population groups with new HF are scarce. 
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Prior work has focused on overall trends in HF risk fac-
tors, which fails to delineate patterns among groups,7 or 
on subgroups at single time-points,8,9 which lack impor-
tant information on changing demography. Using large 
linked national UK clinical databases, this study aimed to 
investigate differences in risk factors among groups with 
new-onset HF in the United Kingdom, by sex, socioeco-
nomic status, and ethnicity and temporal changes over 2 
decades.
METHODS
Study Population
We used the Clinical Practice Research Datalink (CPRD), 
the largest anonymized database of routinely collected pri-
mary care records globally, linked to hospital episode statis-
tics (HES) and Index of Multiple Deprivation data. The CPRD 
includes ≈7% of the UK general population from general 
practices that have consented to contribute data. Included 
patients have been found to be representative of the general 
population in terms of the age, sex, and ethnicity.10 Data is 
collected longitudinally from a patient’s first registration with 
their general practice until they transfer out or die and includes 
their demographic information, clinical consultations, referrals, 
prescriptions, tests, and lifestyle information and has been 
validated for epidemiological research and coding of clinical 
diseases.11 HES data contain details of all inpatient and out-
patient admissions to National Health Service healthcare pro-
viders in England, including admission and discharge dates, 
diagnoses, and procedures taken.12
We included all patients aged ≥30 years who had a first 
HF diagnosis recorded in their CPRD or HES record between 
January 1, 1998 and July 31, 2017, and were eligible for data 
linkage (Figure I in the Data Supplement). Patients in CPRD 
were included if they had a Read diagnostic code for HF in 
their primary care record. Patients in HES were included if they 
had an inpatient HF International Classification of Diseases, 
Tenth Revision discharge code in the primary position. Where 
patients had HF codes in both datasets, the first was used 
as the HF index date. Patients identified in CPRD or HES 
were excluded if they were from a general practice that had 
not contributed a minimum of 12-months of CPRD assessed 
up to standard data, before study entry. We used an updated, 
clinically validated HF CPRD code set,13 and International 
Classification of Diseases, Tenth Revision codes (Tables I and II 
in the Data Supplement). All patients were deemed acceptable 
by CPRD quality control.
Ethical Review
The study protocol was approved by the Independent Scientific 
Advisory Committee for data access (Protocol 18_037R). 
Ethics approval for the use of CPRD data following approval 
from Independent Scientific Advisory Committee is granted by 
a national research ethics committee (05/MRE04/87/AM06). 
Although individual patient consent is not required, all data is 
deidentified, and patients can opt-out of data contribution.
Data and Materials Access
Dr Lawson had full access to all the data in the study and takes 
responsibility for the integrity of the data and the accuracy of 
the data analysis. This study is based in part on data from the 
Clinical Practice Research Datalink obtained under license 
from the UK Medicines and Healthcare products Regulatory 
Agency. However, the interpretation and conclusions contained 
in this report are those of the authors alone. Data access is 
through permissions from CPRD only.
Socioeconomic Status
The patient-level Index of Multiple Deprivation was used as 
a measure of socioeconomic status. The English Indices of 
Deprivation 2010 are measures of deprivation linked to small 
housing areas in England and covering 7 domains.14 When 
domain scores are combined using appropriate weights, a sin-
gle overall Index of Multiple Deprivation is produced, which is 
a useful proxy of individual-level deprivation for use in health 
research. The score was ranked into quintiles, ranging from 
most affluent (quintile 1) to most deprived (quintile 5).
Nonstandard Abbreviations and Acronyms
BMI body mass index
CPRD Clinical Practice Research Datalink
HES hospital episodes statistics
HF heart failure
IHD ischemic heart disease
WHAT IS NEW?
• Following an initial increase in ischemic cause of 
HF, the figures are now falling for women, whereas 
remaining stable in men. Number of comorbidities 
is increasing faster per annum for women than men.
• Difference in age at HF diagnosis between the 
most affluent and most deprived is widening, with 
the most deprived group becoming younger at the 
same rate as the most affluent group are aging. 
Increasing differences in prevalence of comorbidi-
ties and cardiovascular risk factors are also appar-
ent with the most deprived at significantly increasing 
higher risk than the most affluent.
• South Asian and black groups are younger at HF 
onset than whites with higher prevalence of cardio-
metabolic comorbidities.
WHAT ARE THE CLINICAL IMPLICATIONS?
• Decreasing prevalence of cardiovascular risk fac-
tors and increasing prevalence of comorbidities 
before HF onset indicates a need for earlier patient-
centered multimorbidity care.
• Contemporary tailored HF prevention programs 
are required to address group differences and to 
target the worse-off groups to abate the alarming 
projected increase in HF burden and costs over the 
next 2 decades.
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Ethnicity
Ethnicity classification was based on CPRD and HES recording 
using an algorithm, validated against the national UK census 
for ethnicity distribution15 (Figure II in the Data Supplement). 
Ethnicity was categorized into 3 distinct groups for the analyses, 
reflecting the most prevalent ethnic groups in the 2011 census 
in England and Wales,16 as follows white, South Asian, or black. 
Those coded as mixed, other, or unknown had their ethnicity 
status counted as missing. South Asian included Pakistani, 
Indian, Bangladeshi, and other Asian ethnic groups, such as 
Asian British, whereas black includes African, Caribbean, and 
other black groups, such as black British.
Baseline Characteristics
We collected information on ischemic heart disease (IHD) and 
myocardial infarction as well as other common comorbidities. 
We used Read and International Classification of Diseases, 
Tenth Revision codes in CPRD and HES respectively, to ascer-
tain comorbidities recorded up to and including the HF index 
date. We also collected information on other risk factors using 
the most recent measure before study entry, including current 
smoking and alcohol status, body mass index (BMI), systolic 
blood pressure, cholesterol, hemoglobin, and estimated glo-
merular filtration rate.
Statistical Analysis
Baseline characteristics are reported as numbers (%) for cat-
egorical variables, mean (SD) for continuous variables, and 
median (25th and 75th centiles) for skewed data. Overall dif-
ferences in baseline risk factors between groups were esti-
mated using logistic (binary variables) and linear (continuous 
variables) models adjusting for age, sex, socioeconomic status, 
ethnicity, and HF diagnosis year. Absolute differences in risk 
factors between the group categories were calculated com-
paring female with male, the most deprived with most affluent 
and the South Asian and black groups with the white group. 
A sensitivity analysis was performed to estimate overall differ-
ences between groups, restricted to patients with a hospital 
diagnosis of HF only.
To summarize any temporal changes in risk factors, age-
adjusted logistic (binary variables) or linear (continuous vari-
ables) regression models were used. Estimates were calculated 
by sex, socioeconomic status, and ethnicity for 2 time-windows 
at the beginning (1998–2002) and end (2013–2017) of the 
study time period. To investigate trends more closely, the mod-
els were then fitted with a 3-way interaction term between a 
population group, HF diagnosis year, and age. For each group 
category, risk factors were estimated for each calendar year 
using the mean population age. As some of the continuous 
variables were slightly skewed, 1000 bootstrap samples were 
used for the linear regression models. Absolute difference and 
percentage change in each risk factor between 1998 and 
2017 were calculated, as well as mean change per year (trend 
slope). Piecewise linear or logistic regressions were performed 
using “nl hockey” or “loghockey” commands in Stata-MP 14, 
respectively, to identify whether there was a significant change 
in a trend slope. Any difference in the rate of change between 
group categories was examined visually, by plotting graphs of 
predicted risk factors by HF diagnosis year and analytically, by 
the significance level of the coefficient for an interaction term 
between the group and HF index year (as a continuous vari-
able) included in the models also containing age.
To estimate proportions following logistic regression and 
mean values following linear regression, the “Margins” com-
mand in Stata-MP 14 was used. Margins are statistics cal-
culated from predictions of a previously fit model. With the 
exception of age, all estimations were performed at the mean 
population aged 78 years. Stata-MP 14 was used for all analy-
ses, and the significance level was set at P<0.05.
RESULTS
Study Population
There were 108 638 patients with a new HF diagnosis 
during the study time period, 56 294 (51.8) diagnosed in 
the community and 52 344 (48.2%) in the hospital, mean 
age 77.8 (11.7) years, 50.0% female, 18.7% in the most 
affluent group, and 17.0% in the most deprived (Table 1). 
Of the 106 374 patients with ethnicity data (Figure I in 
the Data Supplement), 97 273 (91%) were white, 1842 
(1.7%) South Asian, and 1021 (1.0%) were black. Over-
all, HF patients had a mean of 4 comorbidities at the 
time of diagnosis. Most prevalent comorbidities were 
hypertension (65%), IHD (50%), chronic kidney disease 
(43%), atrial fibrillation (41%), osteoarthritis (36%), dia-
betes mellitus (27%), obesity (23%), cancer (23%), and 
depression (22%). Between the first (1998–2002) and 
last time-window (2013–2017), systolic blood pres-
sure, cholesterol, and smoking reduced, whereas BMI 
increased for all groups.
Overall Differences and 20-Year Trends by Sex
Women were 5 years older than men at HF diagnosis 
(mean, 80.4 SD 10.8 versus 75.1 SD 11.9 years; Table 1) 
and more likely to be diagnosed in hospital (50.5% ver-
sus 45.9%). The 5-year age difference remained follow-
ing adjustment for diagnosis year, socioeconomic status, 
and ethnicity (5.3 years [95% CI, 5.2–5.5]; Table 2). Fol-
lowing the same adjustment, women had 12.6% (95% 
CI, 12.0–13.0) less IHD than men but 0.2 (95% CI, 0.1–
0.2) more comorbidities (Table 2). For other risk factors, 
women were less likely to be a current smoker (19% ver-
sus 24%), but they had significantly higher systolic blood 
pressure (140 versus 136 mm Hg) and cholesterol (4.8 
versus 4.3 mmol/L) than men (Table 1). These differ-
ences remained following adjustment with women also 
having higher BMI (all P<0.001, Table 2).
Although the mean increase in age over time was 
similar between men and women (interaction P=0.863), 
the increasing trend has plateaued since 2011 for 
women (Table 3, Figure 1A). Increasing prevalence of 
IHD was similar among women and men until 2006 but 
then began to diverge with men reaching a plateau and 
women experiencing a 0.5% per annum (pa) reduction 
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thereafter (interaction P=0.002, Table 3; Figure 1B). 
The number of comorbidities at HF onset increased at 
a faster rate in women (+0.20; pa) compared with men 
(+0.16 pa) until 2007, before slowing to a similar growth 
rate afterward (+0.07 pa), but without convergence 
(Table 3, Figure 2A).
For specific comorbidities, men had higher preva-
lence of atrial fibrillation, stroke, chronic obstructive 
pulmonary disease, and cancer than women, with simi-
lar growth rates over time (Table IV in the Data Sup-
plement). Men also had higher prevalence of diabetes 
mellitus, which increased at a significantly faster rate 
than in women (0.7% versus 0.5% pa), showing signifi-
cant separation of trend lines after 2009 (Figure 2B). 
Women had higher levels and significantly faster 
increasing rates of iron deficiency anemia (Figure 2C), 
asthma, and osteoarthritis than men. Prevalence of 
depression (Figure 2D) and obesity remained con-
stantly higher in women than men over time. Prevalence 
of hypertension was also higher in women than men but 
has since converged due to greater increasing rates in 
men (Table IV in the Data Supplement).
Overall Differences and 20-Year Trends by 
Socioeconomic Status
At HF diagnosis, the most deprived group were 4 years 
younger than the most affluent group (mean, 75.2 SD 
12.5 versus 79.2 SD 11.1 years; Table 1), which remained 
following adjustment for sex, ethnicity, and diagnosis 
Table 1. Patient Characteristics by Sex, Socioeconomic, and Ethnicity Status
Characteristics
All  
(N=108 638)
Missing 
(%)
Men 
(N=54 362)
Women 
(N=54 276)
Most Affluent 
(N=20 236)
Most Deprived 
(N=18 403)
White 
(N=97 273)
South Asian 
(N=1842)
Black 
(N=1021)
Age, y 77.8 (11.7) … 75.1 (11.9) 80.4 (10.8) 79.2 (11.1) 75.2 (12.5) 77.8 (11.6) 71.7 (12.3) 68.0 (15.2)
Female 54 276 (50%) … … … 9909 (49%) 9334 (51%) 48 364 (50%) 794 (43%) 501 (49%)
Most affluent 20 236 (19%) 0.2 10 327 (19%) 9909 (18%) … … 18 226 (19%) 263 (14%) 57 (6%)
Most deprived 18 403 (17%) 0.2 9069 (17%) 9334 (17%) … … 16 339 (17%) 405 (22%) 400 (39%)
Community diagnosis 63 879 (58.8) … 32 998 (60.7) 30 829 (56.8) 12 283 (60.7) 10 490 (57.0) 56 127 (57.7) 895 (48.6) 504 (49.4)
Hospital diagnosis 44 759 (41.2) … 21 364 (39.3) 23 447 (43.2) 7953 (39.3) 7913 (43.0) 41 146 (42.3) 947 (51.4) 517 (50.6)
Comorbidities
 Number 4.0 (2.0) … 3.9 (2.0) 4.1 (2.1) 3.9 (2.0) 4.2 (2.1) 4.1 (2.0) 4.4 (2.0) 4.0 (2.1)
 IHD 54 673 (50%) … 30 594 (56%) 24 079 (44%) 9894 (49%) 9746 (53%) 49 579 (51%) 1250 (68%) 413 (40%)
 MI 28 849 (27%) … 17 791 (33%) 11 058 (20%) 5271 (26%) 5134 (28%) 26 308 (27%) 746 (40%) 188 (18%)
 AF 44 163 (41%) … 22 143 (41%) 22 020 (41%) 8702 (43%) 6934 (38%) 41 140 (42%) 486 (26%) 235 (23%)
 Hypertension 70 336 (65%) … 33 794 (62%) 36 542 (67%) 13 124 (65%) 11 897 (65%) 64 085 (66%) 1464 (79%) 804 (79%)
 Diabetes mellitus 28 984 (27%) … 15 331 (28%) 13 653 (25%) 4580 (23%) 5604 (30%) 25 648 (26%) 984 (53%) 448 (44%)
 Stroke 13 453 (12%) … 6831 (13%) 6622 (12%) 2418 (12%) 2376 (13%) 12 132 (12%) 242 (13%) 127 (12%)
 Anemia 13 519 (12%) … 5291 (10%) 8228 (15%) 2365 (12%) 2449 (13%) 12 243 (13%) 442 (24%) 156 (15%)
 Obesity 25 491 (23%) … 12 930 (24%) 12 561 (23%) 3919 (19%) 5090 (28%) 23 455 (24%) 422 (23%) 363 (36%)
 CKD 46 478 (43%) … 20 493 (38%) 25 985 (48%) 8001 (44%) 7251 (39%) 42 207 (43%) 708 (38%) 323 (32%)
 COPD 20 156 (19%) … 11 162 (21%) 8994 (17%) 2834 (14%) 4687 (25%) 18 640 (19%) 204 (11%) 90 (9%)
 Asthma 19 822 (18%) … 9273 (17%) 10 549 (19%) 3262 (16%) 4055 (22%) 18 109 (19%) 435 (24%) 191 (19%)
 Depression 24 102 (22%) … 9537 (18%) 14 565 (27%) 4065 (20%) 4556 (25%) 22 140 (23%) 338 (18%) 154 (15%)
 Osteoarthritis 38 624 (36%) … 15 813 (29%) 22 811 (42%) 7286 (36%) 6476 (35%) 35 528 (37%) 651 (35%) 311 (30%)
 Cancer 24 484 (23%) … 12 629 (23%) 11 855 (22%) 5081 (25%) 3466 (19%) 22 906 (24%) 172 (9%) 150 (15%)
 Dementia 5861 (5%) … 2124 (4%) 3737 (7%) 1105 (5%) 907 (5%) 5264 (5%) 62 (3%) 53 (5%)
Smoking 20 495 (22%) 12.9 11 790 (24%) 8705 (19%) 2985 (17%) 4571 (28%) 17 994 (21%) 265 (16%) 163 (19%)
BMI, kg/m2 26.8  
(23.6–30.8)
20.9 27.0  
(24.1–30.6)
26.6  
(23.0–31.2)
26.3  
(23.4–29.9)
27.4  
(23.8–31.8)
26.9  
(23.7–31.0)
26.6  
(23.6–30.4)
29.0  
(25.2–33.7)
Systolic BP, mm Hg 138.1 (21.7) 9.5 135.9 (20.9) 140.3 (22.3) 137.6 (21.2) 138.4 (21.7) 137.7 (21.5) 135.9 (21.0) 140.2 (21.7)
Cholesterol, mmol/L 4.5 (3.8–5.4) 39.2 4.3 (3.6–5.1) 4.8 (4.1–5.7) 4.5 (3.8–5.4) 4.5 (3.8–5.4) 4.5 (3.8–5.4) 4.3 (3.5–5.1) 4.4 (3.7–5.3)
Hemoglobin, g/dL 13.0 (1.9) 31.9 13.4 (2.0) 12.5 (1.7) 13.0 (1.9) 13.0 (1.9) 13.0 (1.9) 12.5 (1.9) 12.5 (1.9)
eGFR, mL/ 
(min·1.73 m2)
61.7 (20.4) 25.0 64.0 (20.6) 59.3 (20.0) 60.8 (19.8) 63.4 (21.2) 61.5 (20.4) 63.8 (22.0) 68.6 (24.6)
Data are reported as number of patients (%) or mean (SD) or median (25th and 75th centile). AF indicates atrial fibrillation; BMI, body mass index; BP, blood 
pressure; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate; IHD, ischemic heart disease; and 
MI, myocardial infarction.
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year (Table 2). The most deprived group had an adjusted 
4.9% (3.9–6.0) higher prevalence of IHD than the most 
affluent group and 0.4 (0.4–0.4) more comorbidities 
(Table 2). Prevalence of current smoking was 28% in the 
most deprived compared with 17% in the most affluent 
(Table 1) with an 8.0% (7.2–8.9) difference remaining fol-
lowing adjustment (Table 2). The deprived group also had 
a 0.8 kg/m2 (0.7–1.0) higher BMI than the most affluent 
group (Table 2). For each lower quintile of socioeconomic 
status, there was a significant reduction in age at diagno-
sis and a significant increase in number of comorbidities, 
BMI, and prevalence of IHD and smoking (Table III in the 
Data Supplement).
Over time, age in the most affluent group increased 
at a similar annual rate (≈1 month pa) as it reduced in 
the most deprived group (Table 3). This divergence is 
most marked after 2006, following an accelerated age 
increase in the most affluent group (Figure 1A). Despite 
their reducing age, the most deprived group had a faster 
growth rate in the number of comorbidities than the most 
affluent, increasing from a difference of 0.2 in 1998 to 
2002 (3.1; 3.1–3.2 versus 2.9; 2.9–3.0 comorbidities, 
respectively) to 0.6 by 2013 to 2017 (5.1; 5.1–5.2 ver-
sus 4.5; 4.4–4.5; Table 3, Figure 2A). The most deprived 
group also had significantly slower annual reduction 
rates in smoking before 2009 (−1.9% [95% CI, −2.2 
to −1.7]) than the most affluent group (−2.9% [95% CI, 
−3.2 to −2.7] Figure 1C).
For specific comorbidities, the deprived group had 
significantly higher prevalence of most comorbidities 
with the biggest differences for obesity (28% versus 
19%), diabetes mellitus (30% versus 23%; Figure 2B), 
chronic obstructive pulmonary disease (25% versus 
14%; Table 1), which remained following adjustment 
(Table IV in the Data Supplement). The deprived group 
also had higher annual growth rates of anemia (+0.9%; 
0.8–0.1 versus +0.6%; 0.5–0.7) and depression (+0.8%; 
0.6–0.9 versus +0.3%; 0.2–0.4) than the affluent group 
(Figures 2C and 2D). Conversely, the more affluent 
group had a higher annual growth rate of cancer than the 
deprived group (+0.9%; 0.7–1.0 versus +0.6%; 0.5–0.7; 
Table IV in the Data Supplement).
Overall Differences and 20-Year Trends by 
Ethnicity
Age at HF onset differed significantly by ethnicity with 
younger onset in the South Asian group (72 years) and 
back ethnicity group (68 years) compared with the older 
white group (78 years; Table 1). Following adjustment, 
age differences compared with the white group were 
−5.7 (95% CI, −6.2 to −5.2) years for the South Asian 
group and −9.0 (95% CI, −9.9 to −8.2) years for the 
black group (Table 3, Figure 1A). Following same adjust-
ment also including age, compared to the white group, 
the South Asian group had 16.5 % (95% CI, 14.3–18.6) 
more and the black group 10.6% (95% CI, 7.6–13.6) 
less IHD (Table 2). Despite their younger age, the South 
Asian group had similar number of comorbidities to the 
white group (difference: 0.1 [95% CI, 0.1–0.2]), whereas 
the black group had 0.3 (95% CI, 0.2–0.4) less.
For specific comorbidities, the South Asian and black 
groups had significantly less atrial fibrillation, cancer, 
depression, and chronic obstructive pulmonary disease 
but had 12% more hypertension, 24% (South Asian), 
and 13% (black) more diabetes mellitus (Table IV in 
the Data Supplement) and 11% (South Asian) and 3% 
(black) more anemia than the white group. For smoking, 
adjusted prevalence was 6.4% (95% CI, 4.9–8.0) less 
in the South Asian group and 7.3% (95% CI, 5.3–9.2) 
less in the black group than the white group (Table 2). 
When stratified by sex, these differences compared with 
the white group narrowed to 3.0% less for South Asian 
men and 4% less for black men, whereas differences 
increased to 12% less for South Asian women and 11% 
for black women (not shown).
Age increased at a faster annual rate in the South 
Asian group before 2013 (+6 months pa; Figure 1A) 
Table 2. Adjusted Group Differences
Age, y
Comorbidities 
(N) IHD, % Smoking, %
Systolic, 
mm Hg BMI, kg/m2
Cholesterol, 
mmol/L
Hemoglobin, 
gdL
eGFR, mL/
(min·1.73 m2)
Male Ref Ref Ref Ref Ref Ref Ref Ref Ref
Female 5.3  
(5.2 to 5.5)
0.2  
(0.1 to 0.2)
−12.6  
(−13.0 to −12.0)
−2.1  
(−2.6 to −1.6)
3.6  
(3.4 to 3.8)
0.3  
(0.3 to 0.4)
0.6  
(0.6 to 0.6)
−0.7  
(−0.8 to −0.7)
−1.1  
(−1.3 to −0.9)
Most affluent Ref Ref Ref Ref Ref Ref Ref Ref Ref
Most deprived −3.8  
(−4.0 to −3.5)
0.4  
(0.4 to 0.4)
4.9  
(3.9 to 5.8)
8.0  
(7.2 to 8.9)
0.4  
(−0.1 to 0.9)
0.8  
(0.7 to 1.0)
−0.1  
(−0.1 to −0.1)
−0.1  
(−0.1 to −0.0)
−0.1  
(−0.6 to 0.3)
White Ref Ref Ref Ref Ref Ref Ref Ref Ref
South Asian −5.7  
(−6.2 to −5.2)
0.1  
(0.1 to 0.2)
16.5  
(14.3 to 18.6)
−6.4  
(−8.0 to −4.9)
0.9  
(−0.1 to 2.0)
−1.4  
(−1.7 to −1.1)
−0.3  
(−0.3 to −0.2)
−0.7  
(−0.8 to −0.6)
−1.7  
(−2.7 to −0.8)
Black −9.0  
(−9.9 to −8.2)
−0.3  
(−0.4 to −0.2)
−10.6  
(−13.6 to −7.6)
−7.3  
(−9.2 to −5.3)
5.3  
(3.8 to 6.9)
0.02  
(−0.4 to 0.4)
−0.1  
(−0.2 to −0.02)
−0.8  
(−0.9 to −0.7)
0.6  
(−0.9 to 2.0)
All group differences adjusted for age, sex, socioeconomic status, ethnicity, and HF index year. BMI indicates body mass index; eGFR, estimated glomerular filtration 
rate; and IHD, ischemic heart disease.
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Table 3. Predicted Prevalence of Cardiovascular Risk Factors, by Population Group and Calendar Year
Calendar Period Time Trends (1998 to 2017)
Average Annual Change in Risk Factors (95% CI) 
and Year of Any Significant Change in Trend Slope
1998–2002 2013–2017
Absolute Difference 
Over Time % diff
Interaction 
P Value Before Change After
Age in years (95% CI)
 Male 74.9 (74.7 to 75.1) 75.7 (75.5 to 76.0) 1.2 (0.4 to 2.0) 1.6 Ref −0.02  
(−0.08 to 0.04)
2007 0.12  
(0.07 to 0.16)
 Female 79.9 (79.7 to 80.1) 80.7 (80.4 to 80.9) 1.8 (0.9 to 2.6) 2.3 0.863 0.09 (0.06 to 1.12) 2011 −0.06  
(−0.15 to 0.03)
 Most affluent 78.7 (78.4 to 79.0) 79.9 (79.6 to 80.2) 2.3 (1.1 to 3.4) 2.9 Ref 0.03 (−0.07 to 0.12) 2007 0.14 (0.07 to 0.21)
  Most 
deprived
75.7 (75.3 to 76.0) 74.6 (74.1 to 75.1) −1.4 (−2.9 to 0.2) −1.8 <0.001 −0.08  
(−0.11 to −0.05)
N/A −0.08  
(−0.11 to −0.05)
 White 76.9 (76.7 to 77.1) 78.5 (78.3 to 78.7) 2.5 (1.9 to 3.1) 3.3 Ref 0.19 (0.12 to 0.25) 2005 0.08 (0.05 to 0.11)
 South Asian 67.9 (66.3 to 69.5) 73.8 (72.7 to 74.8) 5.4 (2.6 to 8.3) 8.0 <0.001 0.52 (0.35 to 0.69) 2013 −0.23  
(−1.16 to 0.70)
 Black 70.2 (67.7 to 72.7) 68.5 (66.8 to 70.2) 0.9 (−8.7 to 10.4) 1.2 0.122 −0.04  
(−0.24 to 0.16)
N/A −0.04  
(−0.24 to 0.16)
Comorbidities in number
 Male 3.0 (3.0 to 3.0) 4.7 (4.7 to 4.8) 2.3 (2.2 to 2.5) 90.2 Ref 0.16 (0.16 to 0.17) 2007 0.07 (0.16 to 0.17)
 Female 3.1 (3.1 to 3.2) 4.9 (4.9 to 4.9) 2.4 (2.3 to 2.5) 90.7 <0.001 0.20 (0.19 to 0.22) 2007 0.07 (0.06 to 0.08)
 Most affluent 2.9 (2.9 to 3.0) 4.5 (4.4 to 4.5) 2.2 (2.0 to 2.4) 89.7 Ref 0.18 (0.17 to 0.20) 2006 0.07 (0.05 to 0.08)
  Most 
deprived
3.1 (3.1 to 3.2) 5.1 (5.1 to 5.2) 2.6 (2.3 to 2.9) 94.9 <0.001 0.19 (0.18 to 0.21) 2007 0.07 (0.05 to 0.08)
 White 3.1 (3.1 to 3.2) 4.8 (4.8 to 4.8) 2.2 (2.1 to 2.2) 86.0 Ref 0.17 (0.16 to 0.17) 2007 0.07 (0.06 to 0.07)
 South Asian 3.6 (3.3 to 4.0) 5.1 (4.9 to 5.2) 2.7 (1.3 to 4.2) 127.2 0.004 0.20 (0.06 to 0.34) 2004 0.07 (0.05 to 0.09)
 Black 3.2 (2.8 to 3.6) 5.0 (4.7 to 5.2) 0.7 (−0.8 to 2.2) 13.1 0.001 0.10 (0.07 to 0.13) N/A 0.10 (0.07 to 0.13)
Ischemic heart disease in % prevalence
 Male 51.9 (51.0 to 52.8) 57.7 (56.9 to 58.6) 8.1 (4.6 to 11.7) 16.2 Ref 1.1 (0.9 to 1.4) 2006 −0.1 (−0.3 to 0.04)
 Female 41.6 (40.8 to 42.4) 42.7 (41.7 to 43.6) 3.1 (−0.4 to 6.7) 7.9 0.002 0.9 (0.7 to 1.2) 2006 −0.5 (−0.7 to −0.4)
 Most affluent 44.5 (43.1 to 46.0) 48.6 (47.2 to 50.0) 10.9 (5.3 to 16.4) 28.2 Ref 1.0 (0.7 to 1.3) 2008 −0.5 (−0.8 to −0.1)
  Most 
deprived
48.3 (46.8 to 49.7) 53.8 (52.2 to 55.5) 3.8 (−0.02, to 9.9) 7.6 0.415 1.1 (0.8 to 0.1) 2008 −0.5 (−0.9 to −0.1)
 White 48.0 (47.3 to 48.6) 50.4 (49.8 to 51.1) 3.6 (1.9 to 5.3) 10.1 Ref 0.8 (0.6 to 1.0) 2007 −0.4 (−0.5 to −0.2)
 South Asian 67.2 (58.4 to 76.0) 71.9 (68.3 to 75.6) 3.7 (−11.2 to 18.6) 6.7 0.346 1.1 (−0.8 to 3.0) 2007 −0.2 (−1.1 to 0.7)
 Black 44.9 (34.7 to 55.2) 49.1 (43.2 to 54.9) −9.5 (−28.2 to 9.2) −25.6 0.484 −0.4 (−3.0 to 2.2) 2007 0.3 (−1.2 to 1.9)
Smoking in % prevalence
 Male 35.1 (34.2 to 36.1) 11.2 (10.6 to 11.8) −13.5 (−16.7 to −10.2) −46.3 Ref − 3.0 (−3.1 to −2.8) 2009 0.4 (0.1 to 0.6)
 Female 36.4 (34.8 to 38.0) 8.5 (7.6 to 9.3) −11.4 (−14.2 to −8.6) −51.4 0.054 −2.4 (−2.5 to −2.2) 2009 − 0.1 (−0.2 to 0.2)
 Most affluent 37.4 (35.8 to 39.1) 17.6 (16.2 to 19.0) −14.7(−19.1 to −10.3) −64.4 Ref −2.9 (−3.2 to −2.7) 2009 0.1 (−0.2 to 0.4)
  Most 
deprived
37.6 (36.9 to 38.4) 12.4 (11.9 to 12.8) −7.6 (−13.4 to −1.9) −29.0 <0.001 −1.9 (−2.2 to −1.7) 2009 0.1 (−0.4 to 0.6)
 White 31.3 (21.4 to 41.2) 10.1 (7.5 to 12.7) −11.1 (−13.5 to −8.8) −45.0 Ref −2.7 (−2.8 to −2.6) 2009 0.2 (0.1 to 0.4)
 South Asian 39.2 (27.7 to 50.8) 8.5 (5.1 to 12.0) −25.9 (−78.5 to 26.6) −61.0 0.010 −1.7 (−2.7 to −0.7) 2011 1.2 (0.1 to 2.3)
 Black 51.9 (51.0 to 52.8) 57.7 (56.9 to 58.6) −53.1 (−98.2 to −8.0) −82.7 0.718 −3.9 (−6.5 to −1.2) 2006 −0.5 (−0.4 to 0.8)
Body mass index in kg/m2
 Male 26.6 (26.5 to 26.7) 28.3 (28.2 to 28.4) 2.1 (1.7 to 2.6) 8.1 Ref 0.11 (0.08 to 0.14) 2007 0.14 (0.11 to 0.16)
 Female 27.0 (26.9 to 27.1) 29.0 (28.8 to 29.1) 3.0 (2.4 to 3.6) 11.2 0.259 0.12 (0.11 to 0.14) 2013 0.32 (0.15 to 0.50)
 Most affluent 26.3 (26.1 to 26.5) 27.8 (27.7 to 28.0) 2.1 (1.3 to 3.0) 8.1 Ref 0.10 (0.08 to 0.12) 2014 0.20 (0.02 to 0.37)
  Most 
deprived
27.0 (26.9 to 27.2) 29.1 (28.9 to 29.3) 2.8 (2.0 to 3.6) 10.7 0.030 0.07 (0.02 to 0.13) 2008 0.20 (0.15 to 0.25)
 White 26.8 (26.8 to 26.9) 28.6 (28.5 to 28.7) 2.4 (2.0 to 2.8) 9.2 Ref 0.11 (0.10 to 0.12) 2013 0.22 (0.16 to 0.12)
 South Asian 26.4 (25.4 to 27.3) 27.1 (26.6 to 27.5) 3.6 (−2.5 to 9.8) 15.3 0.179 0.29 (−0.73 to 1.31) 2002 0.04 (−0.02 to 0.11)
(Continued )
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compared with a much slower growth in the white group 
(+2 months pa to 2005 then +1 month pa thereafter), 
such that between 1998 to 2002 and 2013 to 2017, 
the gap between the groups narrowed from 9 years to 
5 years (Table 3). The age gap between the black and 
white groups widened from 7 to 10 years during the 
 Black 28.1 (26.7 to 29.6) 30.0 (29.0 to 30.9) 4.0 (−0.8 to 8.8) 15.4 0.211 0.14 (0.03 to 0.24) N/A 0.14 (0.03 to 0.24)
Systolic blood pressure in mm Hg
 Male 143.6 (143.2 to 
144.0)
132.6 (132.3 to 
132.9)
−13.9 (−15.3 to −12.5) −9.5 Ref −1.43  
(−1.52 to −1.34)
2007 −0.03  
(−0.12 to 0.07)
 Female 148.7 (148.2 to 
149.1)
134.6 (134.3 to 
135.0)
−16.3 (−17.9 to −14.7) −10.8 <0.001 −1.74  
(−1.84 to −1.63)
2007 −0.27  
(−0.37 to −0.18)
 Most affluent 145.5 (144.7 to 
146.3)
133.4 (132.9 to 
133.9)
−14.4(−16.7 to −12.1) −9.7 Ref −1.58  
(−1.77 to −1.39)
2007 −0.22  
(−0.36 to −0.08)
  Most 
deprived
146.4 (145.7 to 
147.1)
134.0 (133.4 to 
134.5)
−15.3(−17.8 to −12.9) −10.3 0.901 −1.42  
(−1.58 to −1.27)
2008 −0.12  
(−0.29 to 0.05)
 White 146.4 (146.1 to 
146.8)
133.5 (133.3 to 
133.8)
−15.4 (−16.3 to −14.4) −10.6 Ref −1.61  
(−1.68 to −1.53)
2007 −0.16  
(−0.23 to −0.09)
 South Asian 145.1 (139.7 to 
150.5)
135.5 (133.9 to 
137.1)
−5.5 (−32.0 to 21.0) −2.2 0.002 −1.48  
(−2.26 to −0.70)
2007 −0.01  
(−0.44 to 0.43)
 Black 146.4 (141.6 to 
151.2)
139.8 (137.4 to 
142.3)
−27.8 (−50.1,−5.5) −18.7 0.003 −1.88  
(−3.40 to −0.36)
2005 0.03  
(−0.48 to 0.54)
Cholesterol in mmol/L
 Male 5.1 (5.0 to 5.1) 4.3 (4.2 to 4.3) −1.2 (−1.4 to −1.0) −21.7 Ref −0.13  
(−0.14 to −0.12)
2006 0.00  
(−0.00 to 0.01)
 Female 5.7 (5.6 to 5.7) 4.8 (4.8 to 4.9) −1.2 (−1.4,−1.0) −19.7 0.191 −0.14  
(−0.15 to −0.13)
2007 −0.00  
(−0.01 to 0.11)
 Most affluent 5.2 (5.2 to 5.3) 4.5 (4.5 to 4.6) −1.3 (−1.5 to −1.0) −21.8 Ref −0.12  
(−0.14 to −0.10)
2006 −0.01  
(−0.02 to −0.00)
  Most 
deprived
5.3 (5.2 to 5.4) 4.5 (4.4 to 4.5) −1.0 (−1.3 to −0.7) −17.7 0.396 −0.13  
(−0.15 to −0.11)
2007 0.01  
(−0.00 to 0.02)
 White 5.4 (5.3 to 5.4) 4.5 (4.5 to 4.6) −1.2 (−1.4 to −1.0) −20.6 Ref −0.13  
(−0.14 to −0.12)
2006 −0.00  
(−0.00 to 0.00)
 South Asian 5.3 (5.0 to 5.6) 4.2 (4.1 to 4.4) −0.6 (−8.2 to 7.0) −12.9 0.166 −0.15  
(−0.22 to −0.07)
2005 −0.00  
(−0.02 to 0.02)
 Black 5.4 (4.8 to 6.0) 4.4 (4.3 to 4.5) −0.0(−0.3 to 0.4) 0.1 0.239 −0.12  
(−2.00 to −0.04)
2008 0.12  
(−0.02 to 0.05)
Estimated glomerular filtration rate in mL/(min·1.73 m2)
 Male 65.3 (64.9 to 65.6) 62.7 (62.4 to 63.1) −5.2 (−6.5 to −3.9) −7.6 Ref −1.39  
(−1.53 to −1.25)
2004 0.44  
(0.39 to 0.50)
 Female 64.1 (63.8 to 64.4) 61.9 (61.5 to 62.3) −4.6 (−5.9 to −3.3) −6.8 <0.0001 −1.64  
(−1.78 to −1.5)
2005 0.48  
(0.42 to 0.54)
 Most affluent 64.1 (63.6 to 64.7) 63.0 (62.5 to 63.5) −4.3 (−6.4 to −2.2) −6.3 Ref −1.59  
(−1.82 to −1.35)
2004 0.45  
(0.37 to 0.54)
  Most 
deprived
65.1 (64.6 to 65.6) 62.0 (61.4 to 62.6) −5.3 (−7.5 to −3.1) −7.9 0.007 −1.53  
(−1.76 to −1.31)
2005 0.48  
(0.37 to 0.58)
 White 64.5 (64.3 to 64.8) 62.6 (62.3 to 62.8) −4.5 (−5.3 to −3.7) −6.6 Ref −1.45  
(−1.55 to −1.34)
2005 0.48  
(0.44 to 0.52)
 South Asian 61.8 (58.3 to 65.2) 59.8 (58.2 to 61.4) −14.8 (−31.3 to 1.6) −20.4 0.069 −0.03  
(−0.24 to 0.18)
N/A −0.03  
(−0.24 to 0.18)
 Black 64.1 (60.7 to 67.5) 64.0 (61.7 to 66.4) 5.2 (−8.8 to 19.2) 8.5 0.029 −3.29  
(−7.58 to 1.00)
2002 0.45  
(0.09 to 0.81)
All risk factors are reported in units of measurement for continuous variables, for example, age, number of comorbidities, and in percentages for binary variables, 
for example, smoking. With the exception of age, all risk factors are estimated at the mean population age (78 y). P values for interactions were estimated by fitting an 
interaction term between calendar year (as a continuous variable) and group in regression models for each risk factor also containing age. Slope changes are mean 
change per year. N/A indicates non applicable, no change in slope.
Table 3. Continued
Calendar Period Time Trends (1998 to 2017)
Average Annual Change in Risk Factors (95% CI) 
and Year of Any Significant Change in Trend Slope
1998–2002 2013–2017
Absolute Difference 
Over Time % diff
Interaction 
P Value Before Change After
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same time period. All groups experienced reducing 
smoking rates until 2006, but rates began to increase in 
the white group after 2009 (0.2% [95% CI, 0.1–0.4 pa]) 
and in the South Asian group after 2011 (1.2% [95% CI, 
0.1–2.3 pa]; Figure 1C).
Overall group differences were similar when analy-
ses were restricted to the hospital diagnosed HF group 
(Table V in the Data Supplement).
DISCUSSION
This study includes a large nationally representative 
sample of adult patients with new HF over a 20-year 
time period from 1998 to 2017. The findings indicate an 
important change in HF demography, with HF occurring 
at an older age but with less traditional cardiovascular 
risk factors such as alcohol, smoking, blood pressure, 
and cholesterol and more cardiovascular and noncardio-
vascular comorbidities. However, there were significant 
differences between groups of patients with HF, and 
although some of these differences have reduced over 
time, others have persisted or increased, indicating key 
targets for contemporary tailored prevention programs.
Although previous studies have reported an increas-
ing trend in ischemic cause over time,7 detailed trend 
analysis in this study shows that there has been a shift 
to stable or decreasing proportions of HF patients with 
IHD over the past 10 years. The prevalence of diabetes 
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Figure 1. Known risk factors in patients with new heart failure; trends over 20 years by groups.
Estimated risk factors in people with new heart failure, by calendar year of HF diagnosis between 1998 and 2017. With the exception of age, 
all estimates were calculated at the mean population age (78 y). Spikes indicate 95% CI. Ethnicity graphs are on a different scale and spikes 
are not reported due to wide CIs. P values are to test the difference in trend lines between population groups (labeled interaction P). For the 
ethnicity trends, P values compare South Asian and black ethnicity groups with the white group. A, Mean age in years (y axis); calendar year 
of heart failure diagnosis (x axis). B, Proportion of new heart failure patients with ischemic heart disease (y axis); calendar year of heart failure 
diagnosis (x axis). C, Proportion of new heart failure patients who are current smokers (y axis); calendar year of heart failure diagnosis (x axis). 
D, Mean systolic blood pressure in mm Hg (y axis); calendar year of heart failure diagnosis (x axis).
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mellitus, obesity, hypertension, chronic kidney disease, 
and cancer comorbidities at HF onset are increasing, 
and these factors may be associated with the increas-
ing prevalence of HF with preserved ejection fraction.17 
Diabetes mellitus and obesity are forecast to double over 
the next decade, and an increasing number of cancer 
survivors treated with cardiotoxic cancer treatments also 
means that HF figures, especially HF with preserved 
ejection fraction, may rise.18 Also although the success of 
antismoking strategies has shown significant reduction 
in current smokers among new HF patients, our analy-
ses indicated a worrying shift with increasing proportions 
in the most recent years, particularly in men and ethnic 
minority groups.
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Figure 2. Comorbidities in patients with new heart failure; trends over 20 years by groups.
Estimated comorbidity prevalence in people with new heart failure, by calendar year of HF diagnosis between 1998 and 2017. Prevalence 
figures are estimated at the mean population age (78 y). Spikes indicate 95% CI. Ethnicity graphs are on a different scale, and spikes are not 
reported due to wide confidence intervals. P values are to test the difference in trend lines between population groups (labeled interaction P).  
For the ethnicity trends, P values compare South Asian and black ethnicity groups with the white group. A, Mean number of comorbidities 
present at new heart failure diagnosis (y axis); calendar year of heart failure diagnosis (x axis). B, Proportion of new heart failure patients with 
diabetes mellitus (y axis); calendar year of heart failure diagnosis (x axis). C, Proportion of new heart failure patients with iron deficiency anemia 
(y axis); calendar year of heart failure diagnosis (x axis). D, Proportion of new heart failure patients with depression (y axis); calendar year of 
heart failure diagnosis (x axis).
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Although remaining stable in men, IHD has been 
significantly reducing in women since 2008, alongside 
increasing rates of hypertension, obesity, and anemia, all 
of which are associated with HF with preserved ejection 
fraction.6,15 This sex difference is likely to increase due 
to the older age and faster increasing comorbidity rate 
in women at HF onset. This is important because the 
sex dimorphism in HF is not yet recognized in HF clini-
cal guidelines.19 The complex comorbid profile of women 
with HF with increasing hypertension and obesity may 
partly explain the higher proportion of women diagnosed 
first in hospital, compared with men, and highlights an 
emerging trend for primary prevention that will require 
novel approaches to improve prognosis and health.
Men were around 5 years younger than women at 
the time of HF diagnosis. Sex differences relating to the 
earlier onset of cardiovascular disease in men have been 
extensively debated but remain not fully understood.20,21 
Although this sex difference persisted over time, some 
improvements for men are evident over the past 10 years, 
a likely result of improved primary coronary interventions 
over this period.22 Men also differed to women in hav-
ing higher prevalence of diabetes mellitus, with a faster 
increasing trend over the past 5 years. Increased preva-
lence of diabetes mellitus is likely associated with the 
increased prevalence of ischemic-related HF in men and 
indicates a high-risk group. HF and diabetes mellitus com-
bination is known to increase risk of hospital admissions 
and cardiovascular deaths23,24 and may provide a target 
for early intervention with novel pharmacotherapies, such 
as SGLT2 (sodium-glucose cotransporter 2) inhibitors.25
It is known that higher levels of deprivation are asso-
ciated with developing HF at a younger age and with 
more comorbidities.26 It could be argued that the pres-
ence of prior morbidities may lead to closer monitoring 
and earlier diagnosis of less severe HF in this group. 
However, the worse outcomes and younger age at death 
in the most deprived group27 suggests the contrary, 
that HF is more severe at onset, a likely result of the 
worse cardiovascular profile in this group. Worryingly, our 
study shows a widening socioeconomic gradient in age 
at onset, risk factor prevalence, and comorbidities over 
the past 10 years. This finding with prior evidence on 
increased noncardiovascular admissions and mortality 
in the deprived,4 points to an urgent need for early tar-
geted intervention for patients with HF with high levels 
of deprivation who require more holistic care.28 Beyond 
the public health implications for preventive efforts, the 
disparities by socioeconomic status, and their changes 
over time, may importantly impact global HF trial efforts 
to recruit a homogeneous study population.
Overall, although the South Asian and black groups 
were significantly younger at HF onset than the white 
group, they had similar or better cardiovascular risk pro-
files, similar to those previously reported in a younger 
UK general population.29 Risk factors generally improved 
over time for all groups, but we found important recent 
trend shifts of accelerating BMI growth in white and black 
groups and increasing smoking rates in the South Asian 
group. The earlier onset of HF in ethnic minority groups 
likely reflects higher coprevalence of cardiovascular pre-
morbidities, including hypertension, diabetes mellitus and 
obesity, and higher levels of deprivation, compared with 
the white group. These ethnic differences in the United 
Kingdom have persisted over 2 decades and are similar to 
previous findings in African and white American popula-
tions.6,30,31 In terms of cause, ischemia predominated in the 
South Asian group and hypertension in the black group. 
Although both ethnic minority groups share diabetes mel-
litus as a likely HF precipitator, it is postulated that the 
etiological differences between the groups results from 
differing lipid profiles.32 Better lipid profiles in the black 
group means that hypertension rather than atherosclero-
sis is the likely mediator between diabetes mellitus and 
HF,8 leading to a higher proportion of hypertension-related 
HF with preserved ejection fraction.33 Despite higher lev-
els of hypertension in both ethnic minority groups, preva-
lence of atrial fibrillation was lower than in the white group, 
a finding share with prior reports.34 These findings are cru-
cially important given the global challenge and epidemic 
of noncommunicable diseases in America, Asia, and Africa 
and indicate that HF prevention and treatment are going 
to have to be tailored to individual risk profiles.
Our national population-based study is the largest to 
date to report trend differences in the cause and risk 
factors for HF over 20 years. We included all available 
patients with HF presenting in primary care or hospital 
and used age-adjusted measures of baseline risk fac-
tors to produce comparable and representative propor-
tions across twenty years of incident HF. Although it was 
beyond the scope of this study to investigate outcomes in 
different HF groups, this has been separately explored in 
the patients that were eligible for linkage to death data.27 
This is an observational study, so clinical measurements 
were based on routine data collection, which can be sub-
ject to misclassification and measurement error. However, 
clinical recording in the United Kingdom is supported by 
performance incentives, including the use of echocar-
diography for HF,35 and accuracy of diagnosis within the 
CPRD has been found to be valid for a range of morbidi-
ties.10 We also used clinically validated code sets which 
have high precision including for HF11 and identified 
comorbidities using both primary care and hospital codes. 
However, we cannot rule out that changes in the com-
pleteness of coding over time may have influenced preva-
lence figures. That said, it is less plausible that this would 
preferentially impact patients of certain subgroups and so 
is unlikely to affect trend differences. HF phenotyping in 
terms of ejection fraction status or HF severity was not 
possible in CPRD or HES, so the study does not provide 
these estimates but instead provides the real-world con-
text for the general HF population. Although recording of 
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ethnicity status has been a mandatory requirement since 
1991, the number of South Asian and black patients were 
lower than expected from national UK census data.14 This 
study provides the window into ethnic differences, but 
future HF studies are required in international settings, 
such as Asian-HF,36 to investigate the HF life course and 
how prevention and management might differ for tailored 
patient or population interventions.
CONCLUSIONS
Distinct trend differences exist between HF population 
groups over the past 20 years, with persisting or increas-
ing sex, socioeconomic, and ethnic differences. This 
study represents an epidemiological investigation in a 
developed country but has implications that relate to the 
global health agenda for developed and developing coun-
tries. Contemporary tailored HF prevention programs are 
required to address differences and to target the worse 
off groups to abate the alarming projected increase in 
HF burden and costs over the next 2 decades.
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